Psoriasis and Hypertension Severity: Results from a Case-Control Study

April W. Armstrong1*, Steven W. Lin1, Cynthia J. Chambers1, Mary E. Sockolov1, David L. Chin2

1 Department of Dermatology, University of California Davis, Sacramento, California, United States of America, 2 Center for Healthcare Policy and Research, Graduate Group in Epidemiology, University of California Davis, Sacramento, California, United States of America

Abstract

Background: Epidemiologic studies have provided new insights into the association between psoriasis and cardiovascular diseases. Previous population studies have examined hypertension frequency in psoriasis patients. However, the relationship between severity of hypertension and psoriasis has not been characterized.

Objective: We sought to investigate whether patients with psoriasis have more difficult-to-manage hypertension compared to non-psoriatic hypertensive patients.

Approach: We performed a case-control study using the University of California Davis electronic medical records. The cases were defined as patients diagnosed with both psoriasis and hypertension, and controls were defined as patients with hypertension and without psoriasis. In this identified population, 835 cases were matched on age, sex, and body mass index (BMI) to 2418 control patients.

Key Results: Treatment with multiple anti-hypertensives was significantly associated with the presence of psoriasis using univariate (p<0.0001) and multivariable analysis, after adjusting for diabetes, hyperlipidemia, and race (p<0.0001). Compared to hypertensive patients without psoriasis, psoriasis patients with hypertension were 5 times more likely to be on a monotherapy antihypertensive regimen (95% CI 3.60–7.05), 9.5 times more likely to be on dual antihypertensive therapy (95% CI 6.68–13.65), 16.5 times more likely to be on triple antihypertensive regimen (95% CI 11.01–24.84), and 19.9 times more likely to be on quadruple therapy or centrally-acting agent (95% CI 10.58–37.33) in multivariable analysis after adjusting for traditional cardiac risk factors.

Conclusions: Psoriasis patients appear to have more difficult-to-control hypertension compared to non-psoriatic, hypertensive patients.

Introduction

An expanding number of epidemiologic and immunology studies have provided new insight into the association between psoriasis and cardiovascular diseases [1–9]. The initial link between psoriasis and coronary artery disease was suggested in the 1970s [10]. Since then, multiple population-based studies have suggested an association between these two diseases [7,11–13]. Results from a large population-based study showed an increased relative risk of myocardial infarction (MI) especially in young patients with severe psoriasis [1,14,15]. Psoriasis appears to be an independent risk factor for MI, even after controlling for traditional cardiac risk factors [4,16,17]. Additional population-based studies have supported a relationship between psoriasis and cerebrovascular and peripheral vascular diseases [2,18].

Researchers have long suggested that vascular abnormalities might be present in patients with psoriasis [19]. Since the 1920s, histopathologists have observed the presence of abnormally dilated and tortuous capillaries in the dermal papillae and upper one-third of the dermis in psoriasis lesions [19]. The advent of electron microscopy enabled further characterization of these capillaries. These thin-walled vessels contained erythrocytes, displayed prominent gaps between endothelial cells, and lacked pericytes or surrounding smooth muscle cells [20]. Moreover, dilation of these abnormal capillaries was observed prior to keratinocyte hyperplasia in the early development of psoriasis lesions. Notably, the convoluted capillaries remained apparent in the upper dermis for many months even after cutaneous lesions had completely resolved [21,22].

Previous large population studies have examined the relationship between psoriasis and hypertension and have focused on the frequency of hypertension occurrence in psoriasis patients compared to non-psoriasis patients [3,23–25]. However, to our knowledge, hypertension severity (as measured by complexity of anti-hypertensive regimen) in psoriatic patients compared to non-psoriatic, hypertensive patients has not been described.

The primary aim of the study is to elucidate the relationship between the presence of psoriasis and severity of hypertension, as...
measured by number of anti-hypertensive classes used in each patient. Specifically, we sought to investigate whether patients with psoriasis have more severe hypertension or more difficult-to-manage hypertension compared to non-psoriatic hypertensive patients.

**Methods**

Ethics Statement: This retrospective study was approved by the Institutional Review Board at University of California Davis (UCD). The Institutional Review Board at UCD approved a waiver of informed consent for this study.

In this case-control study, we defined “cases” as patients diagnosed with both psoriasis and hypertension and “controls” as those with hypertension and without psoriasis.

We searched UCD Health System EMR database from January 1, 2004 to July 5, 2009 to identify our study cohort. We initially identified 1044 patients who had ICD-9 codes for both psoriasis and hypertension. From this initial cohort, we performed manual chart review, abstracting medical record individually to ensure that these patients fulfilled the following three criteria: (1) the diagnosis of psoriasis was given by a board-certified dermatologist, (2) the diagnosis of hypertension was made by the primary care physician, a cardiologist, or a nephrologist, and (3) the initial diagnosis of psoriasis was made either before or within 10 years after the diagnosis of hypertension. Of the 1044 patients identified as potential cases through EMR, we excluded 209 patients who did not meet the case definition. We included the remaining 835 patients as cases for the study—those having both psoriasis and hypertension. These cases were frequency-matched in a 1:3 ratio to 2418 controls (non-psoriatic, hypertensive patients) on age, sex, and BMI. Inclusion in the control group required that hypertension was diagnosed by a primary care physician, cardiologist, or nephrologist.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) defines severity of hypertension based on the number and classes of antihypertensive agents [26]. Based on the JNC 7 criteria, we defined hypertension severity based on a patient’s medication regimen: 0 = controlled with lifestyle modifications, 1 = monotherapy (excluding centrally acting agents), 2 = dual therapy (excluding centrally acting agents), 3 = triple therapy (excluding centrally acting agents), 4 = quadruple therapy and/or centrally acting agent. We used anti-hypertension regimen as a measure for hypertension severity rather than discrete blood pressure measures because blood pressure measurements alone while on anti-hypertensive

---

Table 1. Demographic and clinical characteristics of patients with psoriasis and hypertension (cases) and those with hypertension without psoriasis (controls).

| Variable                  | Psoriasis & Hypertension (N = 835) | Hypertension (N = 2418) | P-value |
|---------------------------|------------------------------------|-------------------------|---------|
| **Sex**                   |                                     |                         |         |
| Female                    | 390 47%                            | 1130 47%                | 0.991   |
| Male                      | 445 53%                            | 1288 53%                |         |
| **Age**                   |                                     |                         |         |
| Mean (±SD)                | 61.5±13.1 yr                       | 61.7±12.8 yr            | 0.701   |
| **BMI**                   |                                     |                         |         |
| Mean (±SD)                | 31.0±6.7                           | 30.7±6.2                | 0.28    |
| **Race**                  |                                     |                         |         |
| White                     | 319 38%                            | 1120 46%                | 0.00581 |
| Black                     | 22 2.6%                            | 165 6.8%                |         |
| Asian                     | 14 1.7%                            | 80 3.3%                 |         |
| American Indian           | 4 0.5%                             | 7 0.29%                 |         |
| Other                     | 143 17%                            | 540 22%                 |         |
| Unspecified               | 333 40%                            | 506 20.9%               |         |
| **Smoking**               |                                     |                         |         |
| Yes                       | 454 54%                            | 1237 51%                |         |
| No                        | 381 46%                            | 1181 49%                |         |
| **Type II Diabetes Mellitus** |                                  |                         |         |
| No                        | 381 46%                            | 1181 49%                |         |
| Yes                       | 454 54%                            | 1237 51%                |         |

---

Table 2. Univariate analysis examining relationship between hypertension severity and presence of psoriasis.

| Variable                  | Cases | Controls | Crude OR | 95% CI | P-value |
|---------------------------|-------|----------|----------|--------|---------|
| **Sex**                   |       |          |          |        |         |
| Female                    | 390 47% | 1130 47% |          |        |         |
| Male                      | 445 53% | 1288 53% | 1.00     | 0.86-1.17 | 0.99    |
| **Race**                  |       |          |          |        |         |
| White                     | 319 64% | 1120 59% |          |        |         |
| Black                     | 22 4%  | 165 9%   | 0.47     | 0.30-0.74 | 0.0013  |
| Asian                     | 14 3%  | 80 4%    | 0.61     | 0.34-1.10 | 0.10    |
| American Indian           | 4 0.80% | 7 0.37%  | 2.01     | 0.58-6.90 | 0.27    |
| Other                     | 143 28% | 540 28%  | 0.93     | 0.74-1.16 | 0.52    |
| **Smoking**               |       |          |          |        |         |
| Never                     | 382 47% | 1093 52% |          |        |         |
| Prior Smoking             | 310 39% | 745 36%  | 1.59     | 1.10-1.58 | 0.0025  |
| **Alcohol Use**           |       |          |          |        |         |
| Yes                       | 441 59% | 1119 55% | 1.18     | 0.10-1.40 | 0.05    |
| No                        | 308 41% | 925 45%  |          |        |         |
| **Hypertension**          |       |          |          |        |         |
| Lifestyle Modification    | 113 14% | 1248 54% |          |        |         |
| Monotherapy               | 299 36% | 728 30%  | 4.54     | 3.59-5.74 | <0.0001 |
| Dual Therapy              | 239 29% | 301 12%  | 8.77     | 6.78-11.34 | <0.0001 |
| Triple Therapy            | 148 18% | 116 4.80 | 12.09    | 10.33-19.21 | <0.0001 |
| Quadruple or Central Acting Therapy | 36 4.30% | 25 1%  | 15.90    | 9.22-27.44 | <0.0001 |

---

Fisher’s exact test was used to determine significance. *Student’s t-test was used to determine significance. doi:10.1371/journal.pone.0018227.t001
 climbed two regimens due to its clinical relevance. All statistical analyses were performed using SAS software, version 9.1 (SAS Institute). Two-tailed tests were used for all statistical analyses.

### Results

In this case-control study, the demographic and clinical factors for the cases (psoriatic, hypertensive patients) and controls (non-psoriatic, hypertension patients) are summarized in Table 1. Our study groups had a slight male predominance (53%), mean age of 62, and body mass index of approximately 31.

Our univariate analysis showed that the severity of hypertension, as defined in by the number of anti-hypertensives, was significantly associated with the presence of psoriasis (p<0.0001) (Table 2), and this relationship remains significant after adjusting for diabetes, hyperlipidemia, and race (p<0.0001) using a multivariable conditional logistic regression model (Table 3).

Compared to hypertensive patients without psoriasis, psoriasis patients with hypertension were 5 times more likely by multivariable analysis to be on monotherapy antihypertensive regimen (95% CI 3.60–7.05), 9.5 times more likely to be on dual antihypertensive therapy (95% CI 6.68–13.65), 16.5 times more likely to be on triple antihypertensive regimen (95% CI 11.01–24.84), and 19.9 times more likely to be on quadruple therapy or centrally-acting agent (95% CI 10.58–37.33), after adjusting for diabetes, hyperlipidemia, smoking status, and race. These results suggest a significant correlation between the treatment-refractory hypertension and presence of psoriasis that is independent of other known cardiovascular risk factors.

### Discussion

The precise pathophysiologic mechanisms that underlie psoriasis and hypertension are unknown. Researchers proposed that adipose tissue in psoriasis patients serves as a major source of angiotensinogen, which is subsequently converted to angiotensin II [27]. Angiotensin II not only promotes salt retention by kidneys; it also stimulates T-cell proliferation [28,29]. Angiotensin II also appears to promote inflammation and the development of atherosclerosis [30]. The association between psoriasis and hypertension may also be attributed to the increased oxidative stress in psoriasis patients [31]. Greater levels of reactive oxygen species can damage endothelium-dependent vasodilation.

Some researchers have suggested that increased visceral adipose tissue in psoriasis patients may contribute to hypertension development. Increased visceral adipose tissue may be associated with accumulation of perivascular fat, which can serve as a reservoir for activated effector T cells that promote dysfunction in both hypertension and psoriasis [1]. However, these findings do not entirely explain the persistent, significant association between psoriasis and hypertension after adjustments for BMI.

Other investigators suggest that endothelin-1 may play an important role in the development of hypertension among psoriasis patients. Endothelin-1 is a protein that constricts blood vessels and increase blood pressure, and it is produced by several different cell types including keratinocytes. While the level of endothelin-1 is usually regulated through various mechanisms, their expression appears to be altered in psoriasis patients [32]. Compared to individuals without psoriasis, the level of endothelin-1 appears to be increased in lesional skin and the serum of psoriasis patients. Furthermore, endothelin-1 level appears to correlate with psoriasis disease severity [32]. Increased endothelin-1 levels are thought to exert a greater vasoconstrictive effect on the blood vessels, which contributes to the development of hypertension.

Previous population studies comparing psoriasis patients with the general population have shown a modest increase in the relative risk of developing hypertension (Table 4) [3,23,25,33]. Specifically, in a prospective study among U.S. female nurses, Qureshi et al. found that women with psoriasis experienced an increased risk for developing hypertension (RR 1.17; 95% CI 1.06–1.30) [3]. In a case-control study using a health-maintenance organization database, investigators found modestly increased odds of having hypertension among psoriasis patients (OR1.37, 95% CI: 1.29–1.46) [23]. Most previous population studies have relied solely on ICD-9 diagnostic codes to identify patients with psoriasis. However, due to potential miscategorization errors by providers or coders, not all ICD-9-based diagnoses in the EMR or claims databases reflect actual diagnoses of medical conditions, including psoriasis or...
hypothesis. Therefore, we employed the method of reviewing individual physician notes to ascertain whether patients had physician-diagnosed hypertension or psoriasis.

In this study, we sought to address whether psoriasis patients have more difficult-to-control hypertension compared to hypertensive patients without psoriasis. By defining cases as patients with both hypertension and psoriasis and controls as patients with hypertension alone, we ascertained that psoriasis patients were more likely to require more anti-hypertensive medications than non-psoriatic, hypertensive patients who have hypertension are more likely to have more difficult-to-control hypertension and require a greater number of anti-hypertensive medications than non-psoriatic, hypertensive patients who have hypertension are more likely to have more difficult-to-control hypertension and require a greater number of anti-hypertensive medications than non-psoriatic, hypertensive patients.

The findings of this study need to be interpreted in the context of the study design. In this case-control study, the medical records for the cases and controls have been individually evaluated to ensure that they represent true cases or controls. This method of defining the cases and controls, though time-consuming, allowed for more accurate identification of the comparison groups. While this research methodology does not completely eliminate misclassification errors, it greatly reduces the likelihood of misclassification of cases or controls, a problem frequently encountered when using ICD-9 codes alone in population studies. Despite our best efforts to minimize misclassification errors, it is still possible that a patient with potentially severe hypertension was not on multiple anti-hypertensive medications due to not obtaining regular medical care. Although the current medical literature remains inconclusive at best regarding whether certain anti-hypertensive medications exacerbate psoriasis, it is nevertheless important to consider this possibility in a small number of patients. While we considered assessing psoriasis severity, such assessment is hampered by the lack of consistent PASI or body surface area recordings. Furthermore, in comparison to hypertension that follows a more predictable, progressive course, the clinical course for psoriasis as measured by medications is much more variable over several years. Therefore, the fluctuating nature of psoriasis disease severity makes it potentially problematic to select one data point to define the overall disease severity in a patient.

Our findings contribute to the current literature by elucidating the relationship between psoriasis and hypertension. While previous studies have shown modestly increased odds of having hypertension among psoriasis patients, our study findings suggest that psoriasis patients who have hypertension are more likely to have more difficult-to-control hypertension and require a greater number of anti-hypertensive medications than non-psoriatic, hypertensive patients. These novel findings will contribute to our understanding of the epidemiologic associations between these two conditions and provide impetus for in-depth translational and basic investigations that elucidate shared mechanisms for this epidemiologic observation. Furthermore, the results of this study may benefit physicians who regularly treat hypertensive patients and alert them to the

### Table 4. Studies of prevalence of hypertension among psoriasis patients.

| Author and Journal | Study Design | Number of Psoriasis Patients | Prevalence of Hypertension | P-value |
|--------------------|-------------|------------------------------|---------------------------|---------|
| Armstrong, et al. 2010 (Current study) | Case-Control | 835 | See details in text | See details in text |
| Al Matari, et al. 2010 | Case-Control - computerized patient records | Mild-Moderate - 1661 | OR = 3.597 (95% CI 3.015–4.29) | < 0.001 |
| Severe - 129 | OR = 5.17 (95% CI 3.53–7.55) | < 0.001 |
| Alcobelli, et al. 2009 | Survey - questionnaires | Total - 1376 | Frequency of associated HTN = 12.9% | < 0.001 |
| Smokers (>15 cigarettes per day) | OR = 1.37 (95% CI 1.01–2.03) | |
| Drinkers (>2 glasses/day of wine) | OR = 2.11 (95% CI 1.31–3.40) | |
| Neumann, et al. 2009 | Cross-Sectional Study - UK General Practice Research Database | Mild – 127,706 | OR = 1.16 (95% CI 1.14–1.18) | 95% CI |
| Severe – 3,854 | OR = 1.25 (95% CI 1.13–1.39) | |
| Qureshi, et al. 2009 | Cohort - women aged 27–44 in 1991, completed follow-up questionnaire in 2005 | 78,061 out of the 116671 from the 1991 cohort responded in 2005 | Age Adjusted RR = 1.32 (95% CI 1.19–1.45) | 95% CI |
| Cohen, et al. 2010 | Case-Control – Clall Health Services Database | 12,502 | OR = 1.37 (95% CI 1.29–1.46) | < 0.001 |
| Augustine, et al. 2010 | Case-Control – Health Insurance Data in Germany using ICD-10 codes | 33,981 | OR = 1.73 (95% CI 1.71–1.76) | N/D |
| Wu, et al. 2008 | Case Control - National Health and Wellness Survey | 1127 | HR = 1.49 (95% CI 1.23–1.80) | < 0.01 |
| Kaye, Li, and Jick 2008 | Cohort – General Practice Research Database | 44,164 | HR = 1.09 (95% CI 1.05–1.14) | < 0.001 |
| Sommer, et al. 2006 | Case-Control | 581 | OR 3.27 (95% CI 2.41–4.43) | < 0.001 |

doi:10.1371/journal.pone.0018227.t004
likelihood that the psoriatic patients will likely require more intense hypertensive regimen to achieve adequate blood pressure control, compared to other hypertensive patients.

Acknowledgments
We would like to acknowledge Larry Errecart, the Data Systems Manager at the UC Davis Clinical and Translational Science Center, for his assistance in data collection.

References
1. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, et al. (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130: 1785–1796.
2. Kaye JA, Li L, Jack SS (2005) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159: 895–902.
3. Qureshi AA, Choi HK, Setty AR, Curhan GC (2009) Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145: 379–382.
4. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, et al. (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55: 829–835.
5. Gisondi P, Girolomoni G (2009) Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 35: 313–324.
6. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, et al. (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157: 68–73.
7. Shapiro J, Cohen AD, David M, Horodak E, Chodik G, et al. (2007) The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56: 629–634.
8. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenfeld M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298: 321–328.
9. Huerta C, Rivero E, Rodriguez LA (2007) Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143: 1493–1499.
10. McDonald CJ, Calabresi P (1978) Psoriasis and occlusive vascular disease. Br J Dermatol 99: 469–475.
11. Ludvig RJ, Herzig C, Kostock A, Ochsendorf FR, Zoller TM, et al. (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156: 271–276.
12. Dreher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD (2008) Psoriasis and dyslipidemia: a population-based study. Acta Derm Venereol 88: 561–565.
13. Shapiro Jea (2006) The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56: 629–634.
14. Bochnak WH, Bochnak S, Schon MP (2010) Managing comorbid disease in patients with psoriasis. RMJ 345: b3666.
15. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, et al. (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296: 1735–1741.
16. Mulller A, Akre O, Granath F, Yin L, Lindlof B, et al. (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19: 225–230.
17. Gelfand JM, Troxel AB, Lewis JD, Kudr SK, Shin DB, et al. (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143: 1493–1499.
18. Kimball AB, Robinson D, Jr., Wu Y, Guzzo C, Yelding N, et al. (2008) Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 217: 27–37.
19. Bietmann S (1926) Kapillarmikroskopische untersuchungen bei psoriasis. Dermat Wechsmehr 83.
20. Braverman IM (1972) Electron microscopic studies of the microcirculation in psoriasis. J Invest Dermatol 59: 91–98.
21. Kulla J (1964) Microcirculatory impairment as a factor in inflammatory tissue damage. Ann N Y Acad Sci 116: 1018–1044.
22. Lawler JC, Vineyard WR (1960) The effect of treatment on the vascular component of the psoriatic lesion. Arch Dermatol 82: 190–193.
23. Cohen AD, Weitzman D, Dreibel (2010) Psoriasis and hypertension: a case-control study. Acta Derm Venereol 90: 23–26.
24. Mehta NN, Aftar RS, Shin DB, Neimann AL, Troxel AB, et al. (2009) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J.
25. Prodanovich S, Kiens RB, Kravetz JD, Ma F, Martinez L, et al. (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145: 700–703.
26. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Date of Publication: 2004. Available: http://www.nhlbi.nih.gov/guidelines/hypertension/.
27. Ingoli S, Rohuje K, Gorzelniak K, Jasper J, Sching P, et al. (2005) Weight loss and the renin-angiotensin-alderosterone system. Hypertension 45: 356–362.
28. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LF, et al. (1999) Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693–1701.
29. Jackson SH, Descalas S, Kwon J, Pinto LA, Williams MS (2004) T cells express a phagocytye-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol 5: 819–827.
30. Kim S, Iwase H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11–54.
31. Sowers JR (2002) Hypertension, angiotensin II, and oxidative stress. N Engl J Med 346: 1999–2001.
32. Benfari C, Masi S, Carducci M, D’auria L, Anegiolo F (1998) Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol 78: 22–26.
33. Allozelli E, Petrcelli R, Maccareno M, Altomare G, Argenziano G, et al. (2009) Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 19: 252–256.

Author Contributions
Conceived and designed the experiments: AA. Performed the experiments: SL, CC MS. Analyzed the data: DC. Contributed reagents/materials/analysis tools: AA. Wrote the paper: AA DC.